OUR DRUG PIPELINE
Promising disease product candidates for difficult to treat diseases
ANV221 - Targeting the Cancer Glycobiome
(Not yet FDA/EU approved - for clinical awareness, research, and investor purposes only)
*Oncotarget. 2016; 7:35478-35489. https://doi.org/10.18632/oncotarget.8155
Several solid tumor cancers have been found to upregulate N-glycosylation to fuel one or more of their hallmark behaviors. ANV221 is a novel drug candidate that interrupts this cycle in vivo models leading to:
Disruption of chronic proliferation signaling
Activation of evolutionary conserved apoptosis (cell suicide) pathways
Suppressing cell invasiveness, migration and metastasis
Reversing stem like transformations, thus enhancing tumor vulnerability to other cytotoxic therapies
Low observed toxicity
ANV221 was awarded Orphan Drug Designation for the treatment of Pancreatic Cancer by the FDA.
"PDAC xenograft tumors were disappeared in two weeks."
- Michio Kurosu, PhD University of Tennessee Health Science Center
Viruses and DPAGT1
Two virus families, coronavirus and flavivirus are known to upregulate N-glycosylation. Read our white paper to learn how these viruses may respond to DPAGT1 inhibitors.